It develops and markets autologous bone marrow-derived progenitor cells as regenerative therapeutics for cardiovascular diseases focusing on ischemic heart disease (acute myocardial infarction and chronic ischemic heart disease), and thromboangiitis obliterans.
What does TAO stand for?
TAO stands for Thromboangiitis Obliterans
This definition appears frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of TAO
We have 129 other meanings of TAO in our Acronym Attic
- Terrain Avoidance Override
- Test Analysis Outline
- Test Assisté Par Ordinateur (French: Computer-Assisted Test)
- The ACE ORB (Object Computing, Inc.)
- The Aikido Ohana (martial arts; Japan)
- The Alphabetical Order (Washington, DC rock band)
- The Ancient Order (gaming clan)
- The Ardennes Offensive (war)
- The Autumn Offering (band)
- Thème Apprentissage et Optimisation (French: Theme Learning and Optimization)
Samples in periodicals archive:
A notation is that it also acts against such vascular diseases as thromboangiitis obliterans, or Buerger's disease, and perhaps against arteriosclerosis--a potential option against angioplasty or heart bypass surgery.
3,4) Thromboangiitis obliterans is a nonathero-sclerotic, segmental, inflammatory disease that affects the veins, nerves, and small- and medium-sized arteries of the distal lower and upper extremities.
 Thromboangiitis Obliterans Thromboangiitis obli terans (Buerger's disease) (Fig 3) is an obstructive vascular disease caused by segmental inflammatory and proliferative lesions of the tunica media of small arteries and weins.
It develops and markets autologous bone marrow-derived progenitor cells as regenerative therapeutics for cardiovascular diseases focusing on ischemic heart disease (Acute Myocardial Infarction and Chronic Ischemic Heart Disease), and Thromboangiitis Obliterans, or Buerger's Disease.
The report titled 'India: Peripheral Arterial Disease, Thromboangiitis Obliterans and Critical Limb Ischemia Epidemiology and Markets' is the third in a series published on CLI.
15% should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension or thromboangiitis obliterans.